23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

The assets of failed DNA testing firm 23andMe are being bought for $256 million. Biotechnology firm Regeneron Pharmaceuticals said on Monday it would acquire 23andMe's personal genome service, total health, and research services business lines, and its biobank of customers' genetic samples. Regeneron said San Francisco-headquartered 23andMe would continue to offer all consumer genome services. "We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about th ...